Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

Prior treatment

• 5\. Before using any gene therapy products;
• 6\. Received anti-tumor therapy before infusion, should meet the following any one should be ruled out:
  • treated with systemic corticosteroids therapy within 72 hours (except glucocorticoid physiological replacement therapy, such as prednisone \< 10 mg/d or an equivalent dose of the drug);
  • received within 72 hours of small molecule targeted therapy;
  • 2 weeks received systemic chemotherapy except (pretreatment);
  • four weeks received radiotherapy;

Other illness

• 1\. History of epilepsy or other central nervous system disorders;
• 3\. Active infection of hepatitis B virus, C virus or hepatitis E virus;
• 4\. Active infected persons who are not cured;

Lab values

• 2\. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;

Other

• 7\. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
• 8\. Any unsuitable to participate in this trial judged by the investigator;
• 9\. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.

• 1\. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),
  • R/R T-NHL(meets one of the following conditions) :
• Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments;
• Primary drug resistance;
• Relapse after autologous hematopoietic stem cell transplantation;
  • 2.CD5 expression rate was \>90%;
  • 3\. According to Lugano 2014, there should be at least one evaluable tumor lesion;
  • 4\. Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L);
  • 5\. Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%;
  • 6\. Refers to the pulse oxygen saturation 92% or higher oxygen (state);
  • 7\. Estimated life expectancy of minimum of 12 weeks;
  • 8\. ECOG 0-2;
  • 9\. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;
  • 10\. Those who voluntarily participated in this trial and provided informed consent;